<?xml version='1.0' encoding='utf-8'?>
<document id="29859008"><sentence text="Quantitative systems pharmacology analysis of drug combination and scaling to humans: the interaction between noradrenaline and vasopressin in vasoconstriction."><entity charOffset="110-123" id="DDI-PubMed.29859008.s1.e0" text="noradrenaline" /><entity charOffset="128-139" id="DDI-PubMed.29859008.s1.e1" text="vasopressin" /><pair ddi="false" e1="DDI-PubMed.29859008.s1.e0" e2="DDI-PubMed.29859008.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29859008.s1.e0" e2="DDI-PubMed.29859008.s1.e1" /></sentence><sentence text="Development of combination therapies has received significant interest in recent years" /><sentence text=" Previously, a two-receptor one-transducer (2R-1T) model was proposed to characterize drug interactions with two receptors that lead to the same phenotypic response through a common transducer pathway" /><sentence text=" We applied, for the first time, the 2R-1T model to characterize the interaction of noradrenaline and arginine-vasopressin on vasoconstriction and performed inter-species scaling to humans using this mechanism-based model"><entity charOffset="84-97" id="DDI-PubMed.29859008.s4.e0" text="noradrenaline" /><entity charOffset="102-110" id="DDI-PubMed.29859008.s4.e1" text="arginine" /><entity charOffset="111-122" id="DDI-PubMed.29859008.s4.e2" text="vasopressin" /><pair ddi="false" e1="DDI-PubMed.29859008.s4.e0" e2="DDI-PubMed.29859008.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29859008.s4.e0" e2="DDI-PubMed.29859008.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29859008.s4.e0" e2="DDI-PubMed.29859008.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29859008.s4.e1" e2="DDI-PubMed.29859008.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29859008.s4.e1" e2="DDI-PubMed.29859008.s4.e2" /></sentence><sentence text="" /><sentence text="Contractile data were obtained from in vitro rat small mesenteric arteries after exposure to single or combined challenges of noradrenaline and arginine-vasopressin with or without pretreatment with the irreversible α-adrenoceptor antagonist, phenoxybenzamine"><entity charOffset="126-139" id="DDI-PubMed.29859008.s6.e0" text="noradrenaline" /><entity charOffset="144-152" id="DDI-PubMed.29859008.s6.e1" text="arginine" /><entity charOffset="153-164" id="DDI-PubMed.29859008.s6.e2" text="vasopressin" /><entity charOffset="243-259" id="DDI-PubMed.29859008.s6.e3" text="phenoxybenzamine" /><pair ddi="false" e1="DDI-PubMed.29859008.s6.e0" e2="DDI-PubMed.29859008.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29859008.s6.e0" e2="DDI-PubMed.29859008.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29859008.s6.e0" e2="DDI-PubMed.29859008.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29859008.s6.e0" e2="DDI-PubMed.29859008.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29859008.s6.e1" e2="DDI-PubMed.29859008.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29859008.s6.e1" e2="DDI-PubMed.29859008.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29859008.s6.e1" e2="DDI-PubMed.29859008.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29859008.s6.e2" e2="DDI-PubMed.29859008.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29859008.s6.e2" e2="DDI-PubMed.29859008.s6.e3" /></sentence><sentence text=" Data were analysed using the 2R-1T model to characterize the observed exposure-response relationships and drug-drug interaction" /><sentence text=" The model was then scaled to humans by accounting for differences in receptor density" /><sentence text="" /><sentence text="With receptor affinities set to published values, the 2R-1T model satisfactorily characterized the interaction between noradrenaline and arginine-vasopressin in rat small mesenteric arteries (relative standard error ≤20%), as well as the effect of phenoxybenzamine"><entity charOffset="119-132" id="DDI-PubMed.29859008.s10.e0" text="noradrenaline" /><entity charOffset="137-145" id="DDI-PubMed.29859008.s10.e1" text="arginine" /><entity charOffset="146-157" id="DDI-PubMed.29859008.s10.e2" text="vasopressin" /><entity charOffset="248-264" id="DDI-PubMed.29859008.s10.e3" text="phenoxybenzamine" /><pair ddi="false" e1="DDI-PubMed.29859008.s10.e0" e2="DDI-PubMed.29859008.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29859008.s10.e0" e2="DDI-PubMed.29859008.s10.e1" /><pair ddi="false" e1="DDI-PubMed.29859008.s10.e0" e2="DDI-PubMed.29859008.s10.e2" /><pair ddi="false" e1="DDI-PubMed.29859008.s10.e0" e2="DDI-PubMed.29859008.s10.e3" /><pair ddi="false" e1="DDI-PubMed.29859008.s10.e1" e2="DDI-PubMed.29859008.s10.e1" /><pair ddi="false" e1="DDI-PubMed.29859008.s10.e1" e2="DDI-PubMed.29859008.s10.e2" /><pair ddi="false" e1="DDI-PubMed.29859008.s10.e1" e2="DDI-PubMed.29859008.s10.e3" /><pair ddi="false" e1="DDI-PubMed.29859008.s10.e2" e2="DDI-PubMed.29859008.s10.e2" /><pair ddi="false" e1="DDI-PubMed.29859008.s10.e2" e2="DDI-PubMed.29859008.s10.e3" /></sentence><sentence text=" Furthermore, after scaling the model to human vascular tissue, the model also adequately predicted the interaction between both agents on human renal arteries" /><sentence text="" /><sentence text="The 2R-1T model can be of relevance to quantitatively characterize the interaction between two drugs that interact via different receptors and a common transducer pathway" /><sentence text=" Its mechanistic properties are valuable for scaling the model across species" /><sentence text=" This approach is therefore of significant value to rationally optimize novel combination treatments" /><sentence text="" /></document>